GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Cyclically Adjusted Revenue per Share

Egyptian International Pharmaceutical Investments (CAI:PHAR) Cyclically Adjusted Revenue per Share : E£26.05 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Egyptian International Pharmaceutical Investments's adjusted revenue per share for the three months ended in Dec. 2023 was E£10.424. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is E£26.05 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Egyptian International Pharmaceutical Investments's average Cyclically Adjusted Revenue Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-28), Egyptian International Pharmaceutical Investments's current stock price is E£41.81. Egyptian International Pharmaceutical Investments's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was E£26.05. Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio of today is 1.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egyptian International Pharmaceutical Investments was 1.86. The lowest was 0.97. And the median was 1.30.


Egyptian International Pharmaceutical Investments Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Cyclically Adjusted Revenue per Share Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 20.67 22.90 26.05

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.90 23.69 24.60 25.44 26.05

Competitive Comparison of Egyptian International Pharmaceutical Investments's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio falls into.



Egyptian International Pharmaceutical Investments Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egyptian International Pharmaceutical Investments's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=10.424/129.4194*129.4194
=10.424

Current CPI (Dec. 2023) = 129.4194.

Egyptian International Pharmaceutical Investments Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 3.120 99.695 4.050
201406 3.071 100.560 3.952
201409 3.019 100.428 3.891
201412 2.835 99.070 3.703
201503 3.423 99.621 4.447
201506 3.187 100.684 4.097
201509 3.405 100.392 4.390
201512 2.923 99.792 3.791
201603 3.784 100.470 4.874
201606 3.564 101.688 4.536
201609 4.028 101.861 5.118
201612 3.648 101.863 4.635
201703 4.620 102.862 5.813
201706 4.717 103.349 5.907
201709 4.861 104.136 6.041
201712 5.404 104.011 6.724
201803 5.678 105.290 6.979
201806 5.520 106.317 6.719
201809 5.291 106.507 6.429
201812 5.347 105.998 6.528
201903 7.099 107.251 8.566
201906 6.505 108.070 7.790
201909 6.596 108.329 7.880
201912 6.256 108.420 7.468
202003 5.972 108.902 7.097
202006 5.409 108.767 6.436
202009 5.568 109.815 6.562
202012 5.701 109.897 6.714
202103 6.208 111.754 7.189
202106 5.799 114.631 6.547
202109 6.797 115.734 7.601
202112 7.635 117.630 8.400
202203 7.193 121.301 7.674
202206 6.257 125.017 6.477
202209 7.392 125.227 7.640
202212 9.835 125.222 10.165
202303 7.697 127.348 7.822
202306 9.909 128.729 9.962
202309 9.486 129.860 9.454
202312 10.424 129.419 10.424

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Egyptian International Pharmaceutical Investments's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.81/26.05
=1.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egyptian International Pharmaceutical Investments was 1.86. The lowest was 0.97. And the median was 1.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Egyptian International Pharmaceutical Investments Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Headlines

From GuruFocus